BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24133626)

  • 41. MAP4K4 mediates the SOX6-induced autophagy and reduces the chemosensitivity of cervical cancer.
    Huang H; Han Q; Zheng H; Liu M; Shi S; Zhang T; Yang X; Li Z; Xu Q; Guo H; Lu F; Wang J
    Cell Death Dis; 2021 Dec; 13(1):13. PubMed ID: 34930918
    [TBL] [Abstract][Full Text] [Related]  

  • 42. JARID2 promotes stemness and cisplatin resistance in non-small cell lung cancer via upregulation of Notch1.
    Wang Q; Wu J; Wei H; Huang H; Huang Y; Fang H; Gong X; Sun J; Wu Y; Lei C; Yu J; Hu D
    Int J Biochem Cell Biol; 2021 Sep; 138():106040. PubMed ID: 34246759
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cervical Cancer Patient-Derived Orthotopic Xenograft (PDOX) Is Sensitive to Cisplatinum and Resistant to Nab-paclitaxel.
    Murakami T; Murata T; Kawaguchi K; Kiyuna T; Igarashi K; Hwang HK; Hiroshima Y; Hozumi C; Komatsu S; Kikuchi T; Lwin TM; Delong JC; Miyake K; Zhang Y; Tanaka K; Bouvet M; Endo I; Hoffman RM
    Anticancer Res; 2017 Jan; 37(1):61-65. PubMed ID: 28011474
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antitumor activity of new combination chemotherapy with irinotecan hydrochloride and nedaplatin against human cervical cancer cell lines.
    Yamamoto K; Iwahana M; Kumazawa E; Kakihata K; Abe K; Hirano F; Tohgo A; Hoshiai H; Noda K
    Oncol Rep; 2003; 10(3):593-8. PubMed ID: 12684629
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer.
    Casagrande N; De Paoli M; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
    Gynecol Oncol; 2013 Dec; 131(3):744-52. PubMed ID: 24029417
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.
    Nishi M; Abe Y; Fujimori S; Hamamoto A; Inoue Y; Miyazaki N; Oida Y; Ikoma N; Ohnishi Y; Yamazaki H; Ueyama Y; Nakamura M
    Oncol Rep; 2005 Aug; 14(2):421-4. PubMed ID: 16012725
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CXCR4 enhances cisplatin resistance of human tongue squamous cell carcinoma.
    Zhuang XM; Zhou B
    J Oral Pathol Med; 2019 Feb; 48(2):122-128. PubMed ID: 30554431
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vitamin C in synergism with cisplatin induces cell death in cervical cancer cells through altered redox cycling and p53 upregulation.
    Leekha A; Gurjar BS; Tyagi A; Rizvi MA; Verma AK
    J Cancer Res Clin Oncol; 2016 Dec; 142(12):2503-2514. PubMed ID: 27613187
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Transient increase in squamous cell carcinoma antigen expression in cultured cervical carcinoma CaSki cells in response to exposure to cis-diamminedichloroplatinum.
    Tateiwa Y; Yoshida S; Miyahara Y; Hamana S; Motoyama S; Maruo T
    Tumour Biol; 2003; 24(5):219-27. PubMed ID: 15001834
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro and in vivo antineoplastic activity of a new platinum antineoplastic agent, (R)-(-)-1,1-cyclobutanedicarboxylate (2-aminomethylpyrrolidine)-platinum (II) (DWA2114R) on freshly separated human tumor cells and human tumor xenografts transplanted in nude mice--a comparison with cis-diammine-dichloroplatinum (CDDP).
    Nio Y; Imai S; Shiraishi T; Tsubono M; Morimoto H; Tseng CC; Tobe T
    Anticancer Res; 1991; 11(2):761-7. PubMed ID: 2064331
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of telomerase activity as a measure of tumor cell killing by cisplatin in squamous cell carcinoma cell line.
    Mese H; Ueyama Y; Suzuki A; Nakayama S; Sasaki A; Hamakawa H; Matsumura T
    Chemotherapy; 2001; 47(2):136-42. PubMed ID: 11173816
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
    Nonaka M; Itamochi H; Kawaguchi W; Kudoh A; Sato S; Uegaki K; Naniwa J; Sato S; Shimada M; Oishi T; Terakawa N; Kigawa J; Harada T
    Int J Gynecol Cancer; 2012 Jul; 22(6):922-9. PubMed ID: 22672985
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bone invasion-targeted chemotherapy with a novel anionic platinum complex (3Pt) for oral squamous cell carcinoma.
    Kasahara Y; Endo K; Ueno T; Ueno H; Moriyama-Kita M; Odani A; Yoshizaki T
    Cancer Sci; 2019 Oct; 110(10):3288-3295. PubMed ID: 31348586
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression pattern of cisplatin-induced metallothionein isoforms in squamous cell carcinoma.
    Nakano M; Sogawa CA; Sogawa N; Mishima K; Yamachika E; Mizukawa N; Fukunaga J; Kawamoto T; Sawaki K; Sugahara T; Furuta H
    Anticancer Res; 2003; 23(1A):299-303. PubMed ID: 12680227
    [TBL] [Abstract][Full Text] [Related]  

  • 55. miR-324-5p upregulation potentiates resistance to cisplatin by targeting FBXO11 signalling in non-small cell lung cancer cells.
    Ba Z; Zhou Y; Yang Z; Xu J; Zhang X
    J Biochem; 2019 Dec; 166(6):517-527. PubMed ID: 31778188
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Adenovirus-delivered tissue inhibitor of metalloproteinases-3 transfection increases the sensitivity of cervical cancer cells to cisplatin].
    Zhang Y; Lin C; Qian HL; Lang JH; Fu M; Zhang XY; Liang X; Duan H; Xiang Y
    Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):25-9. PubMed ID: 17575689
    [TBL] [Abstract][Full Text] [Related]  

  • 57. cRGD peptide installation on cisplatin-loaded nanomedicines enhances efficacy against locally advanced head and neck squamous cell carcinoma bearing cancer stem-like cells.
    Miyano K; Cabral H; Miura Y; Matsumoto Y; Mochida Y; Kinoh H; Iwata C; Nagano O; Saya H; Nishiyama N; Kataoka K; Yamasoba T
    J Control Release; 2017 Sep; 261():275-286. PubMed ID: 28666729
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CUL4A silencing attenuates cervical carcinogenesis and improves Cisplatin sensitivity.
    Atri Y; Bharti H; Sahani N; Sarkar DP; Nag A
    Mol Cell Biochem; 2024 May; 479(5):1041-1058. PubMed ID: 37285039
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves.
    Nishiyama M; Yamamoto W; Park JS; Okamoto R; Hanaoka H; Takano H; Saito N; Matsukawa M; Shirasaka T; Kurihara M
    Clin Cancer Res; 1999 Sep; 5(9):2620-8. PubMed ID: 10499641
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells.
    Nakaoka T; Ota A; Ono T; Karnan S; Konishi H; Furuhashi A; Ohmura Y; Yamada Y; Hosokawa Y; Kazaoka Y
    Cell Oncol (Dordr); 2014 Apr; 37(2):119-29. PubMed ID: 24599717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.